Opioids And Psychic Pain: Alkermes Uses High-Profile Stage To Highlight Depression Drug
Biopharma companies working on non-addictive pain drugs and new therapies to treat addiction had a high-profile platform during the most recent meeting of the President’s Commission on opioid abuse. Alkermes made the most of the opportunity.
You may also be interested in...
The novel opioid-system antidepressant is being positioned for adjunctive therapy on top of SSRIs, but Alkermes is eyeing other indications, and better ways to stratify and treat depressed patients.
Alkermes’s announcement of positive findings in the FORWARD-5 trial of its treatment-resistant depression drug ALKS 5461 came as a surprise, given the past two Phase III trials disappointed, but if it can gain approval, the buprenorphine/samidorphan product could meet an unmet need.
Biotech sponsors understandably discuss accelerated approval as an important consideration in development plans. But the head of the US FDA oncology program has a reminder for them: the pathway is intended to serve patients – not drug companies.